158 related articles for article (PubMed ID: 373909)
1. Pharmacokinetic and clinical studies of 24-h infusions of high-dose methotrexate.
Cohen HJ; Jaffe N
Cancer Chemother Pharmacol; 1978; 1(1):61-4. PubMed ID: 373909
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 24-hour infusion of high-dose methotrexate--pharmacokinetics and toxicity.
Goh TS; Wong KY; Lampkin B; O'Leary J; Gnarra D
Cancer Chemother Pharmacol; 1979; 3(3):177-80. PubMed ID: 316745
[TBL] [Abstract][Full Text] [Related]
3. [High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)].
Janka GE; Wiesner H; Bidlingmaier F; Haas RJ
Klin Wochenschr; 1979 Apr; 57(8):411-6. PubMed ID: 313478
[TBL] [Abstract][Full Text] [Related]
4. High dose methotrexate with citrovorum factor in adult resistant lymphoma.
Turman S; Coleman M; Silver RT; Pasmantier M
Cancer; 1977 Dec; 40(6):2823-8. PubMed ID: 338137
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.
Borsi JD; Schuler D; Moe PJ
Cancer Chemother Pharmacol; 1988; 22(1):33-5. PubMed ID: 3260832
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate with a safe rescue program.
Decker DA; Edmonson JH; Gilchrist GS; Kovach JS; Offord JR; Taylor WF
Oncology; 1981; 38(5):262-4. PubMed ID: 6973732
[TBL] [Abstract][Full Text] [Related]
7. Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
Balis FM; Savitch JL; Bleyer WA; Reaman GH; Poplack DG
J Clin Oncol; 1985 Apr; 3(4):485-9. PubMed ID: 3856631
[TBL] [Abstract][Full Text] [Related]
8. Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion.
Wang YM; Kim PY; Lantin E; van Eys DC; Romsdahl MM; Sutow WW
Med Pediatr Oncol; 1978; 4(3):221-9. PubMed ID: 308151
[TBL] [Abstract][Full Text] [Related]
9. Vincristine in the etiology of toxicity of high-dose methotrexate therapy.
Ridgway D; Renholds DC; Neerhout RC; Wolff LJ
Cancer; 1980 Dec; 46(12):2571-2. PubMed ID: 6969624
[TBL] [Abstract][Full Text] [Related]
10. Treatment of primary osteosarcoma with intra-arterial and intravenous high-dose methotrexate.
Jaffe N; Prudich J; Knapp J; Wang YM; Bowman R; Cangir A; Ayala A; Chuang V; Wallace S
J Clin Oncol; 1983 Jul; 1(7):428-31. PubMed ID: 6607977
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate in the plasma and cerebrospinal fluid of children treated with intermediate dose methotrexate.
Rechnitzer C; Scheibel E; Hendel J
Acta Paediatr Scand; 1981 Sep; 70(5):615-8. PubMed ID: 6976674
[TBL] [Abstract][Full Text] [Related]
12. High dose methotrexate followed by citrovorum factor reversal in patients with advanced cancer.
Ambinder EP; Perloff M; Ohnuma T; Biller HF; Holland JF
Cancer; 1979 Apr; 43(4):1177-82. PubMed ID: 312690
[TBL] [Abstract][Full Text] [Related]
13. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy.
Jaffe N; Paed D; Farber S; Traggis D; Geiser C; Kim BS; Das L; Frauenberger G; Djerassi I; Cassady JR
Cancer; 1973 Jun; 31(6):1367-73. PubMed ID: 4541163
[No Abstract] [Full Text] [Related]
14. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
Perez C; Wang YM; Sutow WW; Herson J
Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
[TBL] [Abstract][Full Text] [Related]
15. Safety of delayed leucovorin "rescue" following high-dose methotrexate in children.
Camitta BM; Holcenberg JS
Med Pediatr Oncol; 1978; 5(1):55-9. PubMed ID: 370536
[TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate for the patient with osteogenic sarcoma.
Nirenberg A
Am J Nurs; 1976 Nov; 76(11):1776-80. PubMed ID: 136192
[No Abstract] [Full Text] [Related]
17. High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.
Rosen G; Suwansirikul S; Kwon C; Tan C; Wu SJ; Beattie EJ; Murphy ML
Cancer; 1974 Apr; 33(4):1151-63. PubMed ID: 4544836
[No Abstract] [Full Text] [Related]
18. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
Stoller RG; Hande KR; Jacobs SA; Rosenberg SA; Chabner BA
N Engl J Med; 1977 Sep; 297(12):630-4. PubMed ID: 302412
[TBL] [Abstract][Full Text] [Related]
19. Thirty-six-hour preoperative high-dose methotrexate infusion in patients with squamous carcinoma of the head and neck.
Hande KR; Chretien PB; Elias EG; Goldberg NH; Brooks AE; Chabner BA
Med Pediatr Oncol; 1979; 6(1):39-45. PubMed ID: 440204
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.
Isacoff WH; Eilber F; Tabbarah H; Klein P; Dollinger M; Lemkin S; Sheehy P; Cone L; Rosenbloom B; Sieger L; Block JB
Cancer Treat Rep; 1978 Sep; 62(9):1295-304. PubMed ID: 356984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
